JP2018523689A - ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 - Google Patents

ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 Download PDF

Info

Publication number
JP2018523689A
JP2018523689A JP2018508757A JP2018508757A JP2018523689A JP 2018523689 A JP2018523689 A JP 2018523689A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018523689 A JP2018523689 A JP 2018523689A
Authority
JP
Japan
Prior art keywords
composition
kit
alkyl
agent
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018508757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523689A5 (enExample
Inventor
スティーブン ジョセフ シャトルワース，
スティーブン ジョセフ シャトルワース，
アンドリュー デイビッド ホエール，
アンドリュー デイビッド ホエール，
Original Assignee
カルス セラピューティクス リミテッド
カルス セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カルス セラピューティクス リミテッド, カルス セラピューティクス リミテッド filed Critical カルス セラピューティクス リミテッド
Publication of JP2018523689A publication Critical patent/JP2018523689A/ja
Publication of JP2018523689A5 publication Critical patent/JP2018523689A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018508757A 2015-08-19 2016-08-19 ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 Withdrawn JP2018523689A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1514760.6 2015-08-19
GBGB1514760.6A GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use
PCT/GB2016/052575 WO2017029517A1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Publications (2)

Publication Number Publication Date
JP2018523689A true JP2018523689A (ja) 2018-08-23
JP2018523689A5 JP2018523689A5 (enExample) 2019-07-25

Family

ID=54258859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018508757A Withdrawn JP2018523689A (ja) 2015-08-19 2016-08-19 ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物

Country Status (22)

Country Link
US (3) US10668077B2 (enExample)
EP (1) EP3337477B1 (enExample)
JP (1) JP2018523689A (enExample)
KR (1) KR20180064387A (enExample)
CN (2) CN108348505B (enExample)
AU (1) AU2016307885B2 (enExample)
CA (1) CA2995898A1 (enExample)
DK (1) DK3337477T3 (enExample)
ES (1) ES2939815T3 (enExample)
FI (1) FI3337477T3 (enExample)
GB (1) GB201514760D0 (enExample)
HR (1) HRP20230376T1 (enExample)
HU (1) HUE061615T2 (enExample)
IL (1) IL257499A (enExample)
LT (1) LT3337477T (enExample)
MX (1) MX2018001926A (enExample)
PL (1) PL3337477T3 (enExample)
PT (1) PT3337477T (enExample)
RS (1) RS64095B1 (enExample)
SI (1) SI3337477T1 (enExample)
SM (1) SMT202300063T1 (enExample)
WO (1) WO2017029517A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020059705A1 (ja) * 2018-09-18 2021-08-30 株式会社ヤクルト本社 キノリンカルボキサミド誘導体を用いるがん併用療法
JP2022537925A (ja) * 2019-07-01 2022-08-31 カルス セラピューティクス リミテッド Ｂ細胞リンパ腫の療法に使用するためのｐｉ３ｋ阻害剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010286168B2 (en) 2009-08-20 2014-05-15 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
JP7467423B2 (ja) * 2018-09-11 2024-04-15 キュリス，インコーポレイテッド 亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法
PT3930715T (pt) * 2019-02-27 2024-08-02 Astrazeneca Ab Saracatinib para uso no tratamento de fibrose pulmonar idiopática
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
WO2022105836A1 (en) * 2020-11-19 2022-05-27 Guangzhou Healthquest Pharma Co., Ltd. Combination therapies for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502404A (ja) * 2009-08-20 2013-01-24 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
BE786081A (fr) * 1971-07-13 1973-01-10 Uniroyal Sa Appareil et procede pour maintenir les tringles des bourrelets de pneu
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN1250294A (zh) * 1999-07-27 2000-04-12 邮电部武汉邮电科学研究院 以太网与同步数字体系或同步光网络融合的适配方法
NZ516616A (en) 1999-08-03 2003-07-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005082887A1 (ja) 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. ピリミジン誘導体
CA2567883A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
JP5291616B2 (ja) 2006-04-26 2013-09-18 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
EP2035436B1 (en) 2006-06-26 2011-05-25 UCB Pharma S.A. Fused thiazole derivatives as kinase inhibitors
CN101501035B (zh) * 2006-08-08 2013-01-23 中外制药株式会社 作为pi3k抑制剂的嘧啶衍生物及其用途
JP5313909B2 (ja) 2006-11-13 2013-10-09 アイコス コーポレイション 炎症性疾患および癌の処置のためのチエノピリミジノン
AU2007334343A1 (en) 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
AU2008210455A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
WO2008121257A1 (en) 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
EP2154965A4 (en) 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
CA2742550A1 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CN101849934B (zh) * 2010-05-25 2011-11-09 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
ES2688815T3 (es) 2013-05-10 2018-11-07 Karus Therapeutics Limited Inhibidores de histona desacetilasa novedosos
ES2834638T3 (es) * 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
WO2015054099A1 (en) 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
US20150105383A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514756D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502404A (ja) * 2009-08-20 2013-01-24 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020059705A1 (ja) * 2018-09-18 2021-08-30 株式会社ヤクルト本社 キノリンカルボキサミド誘導体を用いるがん併用療法
JP2022537925A (ja) * 2019-07-01 2022-08-31 カルス セラピューティクス リミテッド Ｂ細胞リンパ腫の療法に使用するためのｐｉ３ｋ阻害剤
JP7691939B2 (ja) 2019-07-01 2025-06-12 コンバライフ （シャンハイ） カンパニー リミテッド Ｂ細胞リンパ腫の療法に使用するためのｐｉ３ｋ阻害剤

Also Published As

Publication number Publication date
EP3337477A1 (en) 2018-06-27
ES2939815T3 (es) 2023-04-27
US20180243313A1 (en) 2018-08-30
SI3337477T1 (sl) 2023-04-28
RS64095B1 (sr) 2023-04-28
IL257499A (en) 2018-07-31
KR20180064387A (ko) 2018-06-14
US11291669B2 (en) 2022-04-05
DK3337477T3 (en) 2023-02-20
HUE061615T2 (hu) 2023-07-28
MX2018001926A (es) 2018-06-19
CA2995898A1 (en) 2017-02-23
AU2016307885B2 (en) 2019-07-25
PL3337477T3 (pl) 2023-07-03
US20230066999A1 (en) 2023-03-02
CN108348505B (zh) 2021-10-12
EP3337477B1 (en) 2023-02-01
SMT202300063T1 (it) 2023-03-17
LT3337477T (lt) 2023-03-10
PT3337477T (pt) 2023-03-20
AU2016307885A1 (en) 2018-03-08
CN108348505A (zh) 2018-07-31
US12257254B2 (en) 2025-03-25
US20210069200A1 (en) 2021-03-11
CN113786409B (zh) 2024-04-02
US10668077B2 (en) 2020-06-02
HRP20230376T1 (hr) 2023-06-23
GB201514760D0 (en) 2015-09-30
FI3337477T3 (fi) 2023-04-27
HK1251467A1 (en) 2019-02-01
CN113786409A (zh) 2021-12-14
WO2017029517A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
US12257254B2 (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
CN120794999B (zh) 作为ras抑制剂以治疗癌症的吲哚衍生物
US11708378B2 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
US9663487B2 (en) Phosphoinositide 3-kinase inhibitors
US10442815B2 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
JP2018528192A (ja) Ｐｉ３ｋ阻害剤およびｈｄａｃ阻害剤を含む組成物
KR20250133996A (ko) Ras 억제제
JP7584802B2 (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト
CA2995902A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
HK40065474A (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
HK1251467B (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200601

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200601